Danaher Co. (NYSE:DHR) Shares Sold by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc reduced its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 10.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 177,112 shares of the conglomerate's stock after selling 19,579 shares during the period. AEGON ASSET MANAGEMENT UK Plc's holdings in Danaher were worth $49,218,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of DHR. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the second quarter worth $25,000. nVerses Capital LLC bought a new stake in shares of Danaher in the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Danaher in the 2nd quarter worth about $51,000. Financial Connections Group Inc. bought a new stake in shares of Danaher in the 2nd quarter worth about $51,000. Finally, Western Pacific Wealth Management LP bought a new stake in shares of Danaher in the 1st quarter worth about $55,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 0.3 %

Shares of NYSE:DHR traded down $0.71 during trading on Friday, reaching $245.39. The stock had a trading volume of 2,941,170 shares, compared to its average volume of 2,802,560. Danaher Co. has a one year low of $192.35 and a one year high of $281.70. The company has a market capitalization of $177.24 billion, a P/E ratio of 46.83, a PEG ratio of 4.55 and a beta of 0.85. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm's 50-day simple moving average is $264.89 and its 200 day simple moving average is $260.71.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analysts' expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher's revenue for the quarter was up 3.1% on a year-over-year basis. During the same period last year, the business earned $2.02 EPS. As a group, research analysts expect that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher's dividend payout ratio (DPR) is presently 20.61%.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DHR. Royal Bank of Canada lowered their target price on shares of Danaher from $333.00 to $311.00 and set an "outperform" rating for the company in a report on Wednesday, October 23rd. UBS Group reduced their price target on shares of Danaher from $309.00 to $305.00 and set a "buy" rating on the stock in a research note on Wednesday, October 23rd. Raymond James reduced their price target on shares of Danaher from $310.00 to $300.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 23rd. Stifel Nicolaus raised their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a "hold" rating in a research note on Wednesday, October 23rd. Finally, Barclays reduced their price target on shares of Danaher from $285.00 to $275.00 and set an "equal weight" rating on the stock in a research note on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.